ciltacabtagene autoleucel Carvykti
Selected indexed studies
- ** (, 2023) [PMID:37934846]
- ** (, 2024) [PMID:39693466]
- Ciltacabtagene autoleucel (Carvykti) for multiple myeloma. (Med Lett Drugs Ther, 2022) [PMID:36384766]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Impact of Manufacturing Procedures on CAR T Cell Functionality. (2022) pubmed
- PMID:37934846 (2023) pubmed
- PMID:39693466 (2024) pubmed
- Ciltacabtagene autoleucel (Carvykti) for multiple myeloma. (2022) pubmed
- PMID:40294198 (2025) pubmed
- Sequence not salvage. (2024) pubmed
- Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. (2024) pubmed
- Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma. (2025) pubmed
- Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective. (2024) pubmed
- Idecabtagene vicleucel (Abecma) for multiple myeloma. (2022) pubmed